Epigral Reports Strong Sales Growth Amid Mixed Financial Metrics in FY24-25

Epigral, a midcap player in the chemicals industry, has recently undergone an evaluation adjustment reflecting changes in its underlying financial metrics and market position. The company has reported a robust annual net sales growth rate of 6.37% for the second quarter of FY24-25, with net sales in the first half of the fiscal year reaching Rs 1,277.26 crore, marking a notable increase of 36.89%.
While the operating profit has shown a decline of 7.65%, Epigral has maintained positive results for three consecutive quarters, achieving its highest PBDIT at Rs 178.43 crore. The company's debt-equity ratio remains low at 0.64 times, suggesting a healthy balance sheet.

In terms of market performance, Epigral has demonstrated resilience, outperforming the broader market with a return of 51.18% over the past year, compared to the BSE 500's 7.04%. The company also boasts a return on capital employed (ROCE) of 22.1 and a PEG ratio of 0.9, indicating that it is trading at a discount relative to its historical valuations.

For more insights on Epigral's financial trends and performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.